A Phase 1b/2, Multicenter, Open-label, Dose-escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 02 May 2017
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Sponsors AbbVie
- 24 Oct 2016 Status changed from active, no longer recruiting to completed.
- 15 Apr 2016 Planned End Date changed from 1 May 2016 to 1 Nov 2016.
- 15 Apr 2016 Planned primary completion date changed from 1 May 2016 to 1 Nov 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History